Lenalidomide Capsule
Product Images NDC 69097-604

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 69097-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cipla Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 01)

Chemical structure of Lenalidomide, showing its molecular framework with characteristic rings and functional groups as depicted in the image.*

FDA Label Image

Figure (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 02)

A Kaplan-Meier survival curve chart showing progression-free survival (months) on the x-axis and survival probability (%) on the y-axis, comparing three treatment groups labeled as Rd Continuous, Rd18, and MPT. The chart includes hazard ratio (HR) values with confidence intervals and a log-rank p-value, along with a table displaying the number of subjects at risk over time for each group. The Rd Continuous group shows higher survival probability over time compared to Rd18 and MPT.*

FDA Label Image

Figure 2 (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 03)

Kaplan-Meier survival curve graph showing overall survival probability (%) over time in months for three treatment groups: Rd Continuous, Rd18, and MPT. The chart includes hazard ratios with 95% confidence intervals comparing these groups and a table indicating the number of subjects at risk during the study period.*

FDA Label Image

Figure 3 (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 04)

A Kaplan-Meier progression-free survival curve comparing Lenalidomide (blue line) versus Placebo (red dashed line) over months, showing higher survival probability with Lenalidomide. It includes a table below the graph indicating the number of subjects at risk over time for both groups.*

FDA Label Image

Figure 4 (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 05)

A Kaplan-Meier survival curve chart comparing progression-free survival over months between Lenalidomide and placebo groups. The y-axis shows survival probability from 0 to 1, and the x-axis represents time in months up to 108. The number of subjects at risk is displayed below at intervals. Lenalidomide is represented by a blue solid line, showing higher survival probability than the red dashed line for placebo. A table below details PFS events and the number of subjects at risk over time.*

FDA Label Image

Image (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 06)

A Kaplan-Meier survival curve chart showing the proportion of subjects over time to progression in months, comparing Lenalidomide/Dexamethasone treatment to Placebo/Dexamethasone. The chart includes hazard ratio (HR) with 95% confidence interval (CI) and a log-rank p-value indicating statistical significance.*

FDA Label Image

Image (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 07)

A survival curve chart showing the proportion of subjects over time to progression in months. It compares two groups: Lenalidomide/Dex and Placebo/Dex, with a hazard ratio (HR) of 0.324 and a log-rank p-value less than 0.001, indicating statistical significance.*

FDA Label Image

Figure 5 (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 08)

This chart is a Kaplan-Meier survival curve comparing progression-free survival over months between two groups: patients treated with Rituximab plus Lenalidomide and patients treated with Rituximab plus placebo. The y-axis shows survival probability, and the x-axis shows duration in months. The graph includes the number of subjects at risk at various time points and indicates a hazard ratio with confidence interval and a significant p-value for comparison.*

FDA Label Image

Container-2.5mg-genvion (8eeb4be1 20a8 4250 B002 Ec6705fb1e18 09)

Label for Lenalidomide Capsules 2.5 mg by Cipla USA Inc. The label includes a warning about potential human birth defects and instructs pharmacists to dispense the Medication Guide to patients. It states the package contains 28 capsules and provides storage instructions and manufacturer details for Cipla Ltd and Cipla USA Inc. The NDC is 69097-604-73.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.